Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10587710 | Bioorganic & Medicinal Chemistry Letters | 2013 | 9 Pages |
Abstract
Triclosan is a potent inhibitor of Toxoplasma gondii enoyl reductase (TgENR), which is an essential enzyme for parasite survival. In view of triclosan's poor druggability, which limits its therapeutic use, a new set of B-ring modified analogs were designed to optimize its physico-chemical properties. These derivatives were synthesized and evaluated by in vitro assay and TgENR enzyme assay. Some analogs display improved solubility, permeability and a comparable MIC50 value to that of triclosan. Modeling of these inhibitors revealed the same overall binding mode with the enzyme as triclosan, but the B-ring modifications have additional interactions with the strongly conserved Asn130.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Gang Cheng, Stephen P. Muench, Ying Zhou, Gustavo A. Afanador, Ernest J. Mui, Alina Fomovska, Bo Shiun Lai, Sean T. Prigge, Stuart Woods, Craig W. Roberts, Mark R. Hickman, Patty J. Lee, Susan E. Leed, Jennifer M. Auschwitz, David W. Rice, Rima McLeod,